According to the Zhitong Finance App, Weijun Biotechnology (00660.HK) announced that the group expects to make a profit of not less than HK$30 million for the year ending June 30, 2026, while the net loss for the same period in 2025 is about HK$10.7 million. The forecast for this year turned into a profit, mainly due to a significant improvement in the actual operating performance and prospects of cash generating units producing and selling modified starch, which led to a one-time refund of around HK$52.1 million in property, plant and equipment impairment losses. The relevant amount was also partially offset by the return of deferred tax assets of approximately HK$15 million.

According to the Zhitong Finance App, Weijun Biotechnology (00660.HK) announced that the group expects to make a profit of not less than HK$30 million for the year ending June 30, 2026, while the net loss for the same period in 2025 is about HK$10.7 million. The forecast for this year turned into a profit, mainly due to a significant improvement in the actual operating performance and prospects of cash generating units producing and selling modified starch, which led to a one-time refund of around HK$52.1 million in property, plant and equipment impairment losses. The relevant amount was also partially offset by the return of deferred tax assets of approximately HK$15 million.